Post-marketing requirements and commitments

At Roche and Genentech, patient safety is a priority. These post-authorisation safety studies demonstrate our commitment.

Please click the icons to learn more


DMT, disease-modifying therapies; LMP, last menstrual period; OCR, ocrelizumab; pwMS, people with MS; SAEs, serious adverse events; US, United States.


M-XX-00007224 (Date of preparation: October 2021)